Too much of a good thing, it turns out, is a concept that applies to oxygen. And researchers at the University of California at San Francisco are working on a small molecule, Hypoxystat, that can lower tissue oxygen levels and prevent damage when oxygen levels are too high. When administered to mice with the rare mitochondrial disorder Leigh syndrome, the molecule more than tripled their average lifespan.
Whole genome sequencing has substantially accelerated the pace of discovery of genes that cause rare diseases, but while this has brought the diagnostic odyssey of some patients to a conclusion, 50% to 80% remain undiagnosed after initial analysis. Researchers in the U.K. have now developed a new framework for analyzing sequence data at a cohort level. Applying this method to almost 35,000 undiagnosed rare disease patients led to the identification of 141 new disease-gene associations.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and Zhejiang University have jointly discovered N2-3-fluoro-5-substituted phenyl-2-aminopyrimidine derivatives.
Work at the Chinese University of Hong Kong has led to the identification of bilobalide derivatives reported to be useful for the treatment of cancer, Alzheimer’s and Parkinson’s diseases.
The Council of Scientific and Industrial Research (India) has synthesized new benzo[de]isoquinoline-1,3-dione-based fluorophore probes acting as decaprenylphosphoryl-β-D-ribose oxidase (DprE1) (M. tuberculosis) inhibitors reported to be useful for the diagnosis and treatment of tuberculosis.
Kind Pharmaceuticals LLC has patented substituted benzocyclobutene compounds acting as erythropoietin (EPO) production inhibitors reported to be useful for the treatment of cancer and polycythemia.
Epstein-Barr virus (EBV), a member of the herpesvirus family, is a highly common human pathogen that can remain latent in B lymphocytes after the primary infection. Although this latent state is frequently asymptomatic, in some cases, it can lead to the development of malignancies such as Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, and some gastric cancer subtypes.
Current decolonization methods for methicillin-resistant Staphylococcus aureus (MRSA) face several challenges, including resistance development or microbiome disruption. Hypharm GmbH has presented data regarding their recombinant chimeric bacteriophage endolysin HY-133 for the potential treatment of MRSA infection. HY-133 targets S. aureus and its design combines the CHAP domain from phage K with the cell wall-binding domain of lysostaphin.